Drugs in Dev. Oncology
Discovery
Sweden 
Anocca Raises SEK 400 Million for Large-Scale Development of Cancer Cell Therapies
Details : The financing will develop the company's unique process that enables discovery and manufacture of next generation TCR-T-based cell therapies for cancer on an industrial scale. The financing also allows Anocca to progress the company's first products into...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 31, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Dong-A ST Co., Ltd.
Deal Size : Undisclosed
Deal Type : Termination
Dong-A ST and Beactica Therapeutics Mutually Agree to Conclude Oncology Collaboration
Details : As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global rights for further development and commercialization for different compounds series developed during the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Dong-A ST Co., Ltd.
Deal Size : Undisclosed
Deal Type : Termination
Details : Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica's programme.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 02, 2021
Reset All
